Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)

Nancy Yen, Constantin G. Ioannides, Kai Xu, Stephen G. Swisher, David D. Lawrence, Bonnie L. Kemp, Adel K. El-Naggar, Richard J. Cristiano, Bingliang Fang, Bonnie S. Glisson, Waun K. Hong, Fadlo R. Khuri, Jonathan M. Kurie, J. Jack Lee, Jin S. Lee, James A. Merritt, Tapas Mukhopadhyay, Jonathan C. Nesbitt, Dao Nguyen, Roman Perez-Soler & 6 others Katherine M W Pisters, Joe B. Putnam, David S. Schrump, Dong M. Shin, Garrett L. Walsh, Jack A. Roth

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.

Original languageEnglish (US)
Pages (from-to)530-536
Number of pages7
JournalCancer Gene Therapy
Volume7
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Tumor Suppressor Protein p53
Humoral Immunity
Adenoviridae
Cellular Immunity
Aleurites
Lymphocytes
Antigens
Human Adenoviruses
Injections
Neutralizing Antibodies
Transgenes
Non-Small Cell Lung Carcinoma
Antibody Formation
Epitopes
Neoplasms
Proteins
Peptides
Therapeutics
Serogroup

Keywords

  • Adenovirus vector
  • Anti-p53 antibodies
  • Lung cancer
  • Lymphocyte proliferation
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). / Yen, Nancy; Ioannides, Constantin G.; Xu, Kai; Swisher, Stephen G.; Lawrence, David D.; Kemp, Bonnie L.; El-Naggar, Adel K.; Cristiano, Richard J.; Fang, Bingliang; Glisson, Bonnie S.; Hong, Waun K.; Khuri, Fadlo R.; Kurie, Jonathan M.; Lee, J. Jack; Lee, Jin S.; Merritt, James A.; Mukhopadhyay, Tapas; Nesbitt, Jonathan C.; Nguyen, Dao; Perez-Soler, Roman; Pisters, Katherine M W; Putnam, Joe B.; Schrump, David S.; Shin, Dong M.; Walsh, Garrett L.; Roth, Jack A.

In: Cancer Gene Therapy, Vol. 7, No. 4, 2000, p. 530-536.

Research output: Contribution to journalArticle

Yen, N, Ioannides, CG, Xu, K, Swisher, SG, Lawrence, DD, Kemp, BL, El-Naggar, AK, Cristiano, RJ, Fang, B, Glisson, BS, Hong, WK, Khuri, FR, Kurie, JM, Lee, JJ, Lee, JS, Merritt, JA, Mukhopadhyay, T, Nesbitt, JC, Nguyen, D, Perez-Soler, R, Pisters, KMW, Putnam, JB, Schrump, DS, Shin, DM, Walsh, GL & Roth, JA 2000, 'Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)', Cancer Gene Therapy, vol. 7, no. 4, pp. 530-536.
Yen, Nancy ; Ioannides, Constantin G. ; Xu, Kai ; Swisher, Stephen G. ; Lawrence, David D. ; Kemp, Bonnie L. ; El-Naggar, Adel K. ; Cristiano, Richard J. ; Fang, Bingliang ; Glisson, Bonnie S. ; Hong, Waun K. ; Khuri, Fadlo R. ; Kurie, Jonathan M. ; Lee, J. Jack ; Lee, Jin S. ; Merritt, James A. ; Mukhopadhyay, Tapas ; Nesbitt, Jonathan C. ; Nguyen, Dao ; Perez-Soler, Roman ; Pisters, Katherine M W ; Putnam, Joe B. ; Schrump, David S. ; Shin, Dong M. ; Walsh, Garrett L. ; Roth, Jack A. / Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). In: Cancer Gene Therapy. 2000 ; Vol. 7, No. 4. pp. 530-536.
@article{e7011c371c8a42c39afa718eb39e0ae1,
title = "Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)",
abstract = "The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.",
keywords = "Adenovirus vector, Anti-p53 antibodies, Lung cancer, Lymphocyte proliferation, p53",
author = "Nancy Yen and Ioannides, {Constantin G.} and Kai Xu and Swisher, {Stephen G.} and Lawrence, {David D.} and Kemp, {Bonnie L.} and El-Naggar, {Adel K.} and Cristiano, {Richard J.} and Bingliang Fang and Glisson, {Bonnie S.} and Hong, {Waun K.} and Khuri, {Fadlo R.} and Kurie, {Jonathan M.} and Lee, {J. Jack} and Lee, {Jin S.} and Merritt, {James A.} and Tapas Mukhopadhyay and Nesbitt, {Jonathan C.} and Dao Nguyen and Roman Perez-Soler and Pisters, {Katherine M W} and Putnam, {Joe B.} and Schrump, {David S.} and Shin, {Dong M.} and Walsh, {Garrett L.} and Roth, {Jack A.}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "530--536",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)

AU - Yen, Nancy

AU - Ioannides, Constantin G.

AU - Xu, Kai

AU - Swisher, Stephen G.

AU - Lawrence, David D.

AU - Kemp, Bonnie L.

AU - El-Naggar, Adel K.

AU - Cristiano, Richard J.

AU - Fang, Bingliang

AU - Glisson, Bonnie S.

AU - Hong, Waun K.

AU - Khuri, Fadlo R.

AU - Kurie, Jonathan M.

AU - Lee, J. Jack

AU - Lee, Jin S.

AU - Merritt, James A.

AU - Mukhopadhyay, Tapas

AU - Nesbitt, Jonathan C.

AU - Nguyen, Dao

AU - Perez-Soler, Roman

AU - Pisters, Katherine M W

AU - Putnam, Joe B.

AU - Schrump, David S.

AU - Shin, Dong M.

AU - Walsh, Garrett L.

AU - Roth, Jack A.

PY - 2000

Y1 - 2000

N2 - The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.

AB - The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.

KW - Adenovirus vector

KW - Anti-p53 antibodies

KW - Lung cancer

KW - Lymphocyte proliferation

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=0034085041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034085041&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 530

EP - 536

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 4

ER -